CV Technologies reports first profitable year

Guest Contributor
January 24, 2005

The Edmonton developers of an herbal remedy for colds and flu reported its first profitable year since the biotech company was founded in 1992. CV TechnologiesCOLD-fX product accounted for more than 80% of sales, boosting the start-up’s net profit to $150,918 for the year ending September 30. Total sales for FY04 were $6.41 million, an increase of 316% from $1.54 million a year earlier. Q1/05 registered a spectacular $11.3 million in sales, up 542% over Q1/04. In November, CV Technologies announced the Industrial Research Assistance Program would fund a pre-clinical study, in collaboration with McGill Univ, to investigate the effects of CVT-E002 (the active ingredient in COLD-fX) in treating immune deficiency related to cancer....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.